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Abstract
Background: Recent research has emphasized that the human circadian rhythm system is differentially sensitive to short
wavelength light. Light treatment devices using efficient light-emitting diodes (LEDs) whose output is relatively
concentrated in short wavelengths may enable a more convenient effective therapy for Seasonal Affective Disorder
(SAD).
Methods: The efficacy of a LED light therapy device in the treatment of SAD was tested in a randomized, double-blind,
placebo-controlled, multi-center trial. Participants aged 18 to 65 with SAD (DSM-IV major depression with seasonal
pattern) were seen at Baseline and Randomization visits separated by 1 week, and after 1, 2, 3 and 4 weeks of treatment.
Hamilton Depression Rating Scale scores (SIGH-SAD) were obtained at each visit. Participants with SIGH-SAD of 20 or
greater at Baseline and Randomization visits were randomized to active or control treatment: exposure to the Litebook
LED treatment device (The Litebook Company Ltd., Alberta, Canada) which delivers 1,350 lux white light (with spectral
emission peaks at 464 nm and 564 nm) at a distance of 20 inches or to an inactivated negative ion generator at a distance
of 20 inches, for 30 minutes a day upon awakening and prior to 8 A.M.
Results: Of the 26 participants randomized, 23 completed the trial. Mean group SIGH-SAD scores did not differ
significantly at randomization. At trial end, the proportions of participants in remission (SIGH-SAD less than 9) were
significantly greater (Fisher's exact test), and SIGH-SAD scores, as percent individual score at randomization, were
significantly lower (t-test), with active treatment than with control, both in an intent-to-treat analysis and an observed
cases analysis. A longitudinal repeated measures ANOVA analysis of SIGH-SAD scores also indicated a significant
interaction of time and treatment, showing superiority of the Litebook over the placebo condition.
Conclusion: The results of this pilot study support the hypothesis that light therapy with the Litebook is an effective
treatment for SAD.
Trial registration: Clinicaltrials.gov: NCT00139997
Published: 7 August 2007
BMC Psychiatry 2007, 7:38 doi:10.1186/1471-244X-7-38
Received: 10 April 2007
Accepted: 7 August 2007
This article is available from: http://www.biomedcentral.com/1471-244X/7/38
© 2007 Desan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Psychiatry 2007, 7:38 http://www.biomedcentral.com/1471-244X/7/38
Page 2 of 8
(page number not for citation purposes)
Background
Seasonal Affective Disorder (SAD, winter depression) is a
well-recognized form of recurrent depressive disorder,
characterized by typical and atypical (increased appetite,
weight, sleep and fatigue) depressive symptomatology
and a distinct seasonal nature [1,2]. SAD is thought to be
related to natural seasonal variations in light levels. Bright
light therapy – exposure of the patient each morning to
bouts of artificially produced high intensity light – has
been shown to produce amelioration of depressive symp-
toms. Over 70 trials addressing the efficacy of light ther-
apy have now been conducted, including 2 large
controlled trials [3,4] which demonstrated clear efficacy.
Light therapy was found to be similar in efficacy to treat-
ment with fluoxetine in a large controlled trial [5]. Several
meta-analyses have found that light treatment is effective
for SAD [6-8]. While light therapy appears to be an effica-
cious form of treatment, the traditional mode of delivery
via a relatively large and bulky light box can be cumber-
some for patients. Finding easier and briefer forms of
treatment has been a major goal of the field.
Light therapy using light-emitting diodes (LEDs) may
offer advantages over conventional light boxes based on
fluorescent or incandescent sources. First, recent data indi-
cate that the human circadian rhythm system is most sen-
sitive to light with wavelength in the range 450 – 480 nm
[9-11]. LEDs can be selected to emit light with energy con-
centrated in this range, while fluorescent and incandes-
cent sources emit across the visible spectrum. Although
the role of the circadian rhythm system in the pathophys-
iology of SAD is unclear [12], one study has shown that
LED-generated blue light (398 lux, peak energy output
around 468 nm) was more effective than LED-generated
red light (23 lux, peak output around 654 nm) [13]. Sec-
ondly, LEDs are more efficient and lighter than tradition-
ally used fluorescent tubes, and may permit significantly
smaller and lighter treatment devices. The aim of the
present study was to conduct a randomized placebo-con-
trolled trial to test the efficacy of a white LED device
whose light emission was relatively concentrated in
shorter wavelengths (the "Litebook", The Litebook Com-
pany Ltd., Alberta, Canada). Since negative ion generators
have been reported to be effective in treatment of SAD
[14], a "credible placebo" design similar to that of East-
man and colleagues [4], in which an inactivated negative
ion generator was used as a "no light" control condition,
was employed. The results suggest that treatment with the
Litebook LED device is an effective treatment for SAD.
Methods
Study Protocol
This is a multi-center, randomized, double-blind, parallel-
group clinical trial of light therapy for participants with
SAD (winter type). Participants were seen at a Baseline
Visit, a Randomization Visit, and after 1, 2, 3 and 4 weeks
of treatment. Participants who appeared to meet the inclu-
sion criteria and not meet exclusion criteria at the Baseline
Visit were invited to return in 1 week for a Randomization
Visit. At this visit participants who continued to meet
study criteria were issued either an active light treatment
device or a placebo inactivated ion generator. Participants
were seen at weekly intervals during 4 weeks of treatment.
Participants were enrolled between October 1 and March
1 to reduce confounding effects of natural remission as
expected in the spring.
Severity of depressive symptoms was rated at each visit
using a 24-item SIGH-SAD, a scripted version of the Ham-
ilton Depression Rating Scale [15] modified to reflect bet-
ter the atypical symptomatology of SAD [16]. This version
of the SIGH-SAD consists of the HDRS 17-item scale plus
the first 7 atypical items (i.e., excluding Reverse Diurnal
Variation). At the Randomization Visit and the subse-
quent 4 visits, SIGH-SAD ratings were carried out by a cli-
nician blinded to the assigned treatment device. The
blinded clinician also completed a systematic inquiry
about any adverse events. A separate unblinded clinician
dispensed and demonstrated the treatment device at the
Randomization Visit, and was available at subsequent vis-
its if required.
The study was conducted at 5 sites, in New Haven (USA),
Vancouver, Montreal and Ottawa (Canada), and Gronin-
gen (The Netherlands). The research protocol was
approved by applicable institutional review boards and
met standards established by the Helsinki Declaration,
and participants signed appropriate consent forms. The
trial was registered at the U.S. National Institutes of
Health clinical trials database [17].
Participants
Participants were recruited through media advertisements
or professional referrals, screened by experienced inter-
viewers by telephone, and if appropriate invited for a
Baseline Visit. At this visit, participants received a full psy-
chiatric evaluation, physical exam, urine toxicology for
commonly abused substances, and urinary beta-HCG for
female participants. Participants were required to be
between ages 18 and 65, to have a DSM-IV diagnosis of
SAD (major depressive episode, with seasonal pattern,
winter type [18] and to have a SIGH-SAD score of 20 or
greater. Diagnosis was established with the Structured
Clinical Interview for DSM-IV (SCID) [19]. Participants
also completed the Morningness-Eveningness Question-
naire (MEQ), a measure of preference for activity in the
early or late part of the day [20].
Participants were told that the study involved treatment
with either a new light treatment device or a negative ionBMC Psychiatry 2007, 7:38 http://www.biomedcentral.com/1471-244X/7/38
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generator, that both types of treatment were experimental,
and that the study was placebo-controlled. In particular,
participants were told that one half of the devices in the
study were modified in such a way that the investigators
did not expect the device to be efficacious. In order to
demonstrate informed consent, participants had to dem-
onstrate understanding that if they participate they have a
one in two chance of being assigned to treatment expected
to be inactive for 4 weeks.
Exclusion criteria were: significant medical illness, any ret-
inal disease or medical disorder associated with retinal
disease; pregnancy; use of photosensitizing medications,
mood-altering medications, light therapy or other treat-
ment for SAD within 1 week of the Baseline Visit (except
within 4 weeks in the case of pharmacological antidepres-
sant agents); initiation of psychotherapy within 3 months
of the Baseline Visit, except where terminated by the par-
ticipant prior to this visit; current organic mental disorder,
panic disorder, anorexia or bulimia nervosa, obsessive-
compulsive disorder or posttraumatic stress disorder; a
history of any psychotic disorder or bipolar I disorder
(history of manic episode); a history of substance use dis-
order not in full remission for at least one year; unstable
sleep or mood patterns (such as severe premenstrual syn-
drome); previous unsuccessful trial of light therapy with
an accepted device for at least 2 weeks; inability to provide
informed consent; poor likelihood of complying reliably
with study requirements; suicidal risk or other factor mak-
ing trial participation clinically inappropriate. Partici-
pants were required to have a habitual sleep onset time
before 1 A.M., and a habitual sleep end time before 9
A.M., prior to entry in the trial. Participants were required
to agree to avoid other treatments for SAD or excluded
medications, alteration of daily schedule to change light
exposure, or travel to sunny destinations, to maintain a
stable sleep schedule, and if female and potentially fertile
to use an appropriate form of contraception during the
trial.
Treatment Devices
At the Randomization Visit, eligible participants were
issued an active or control treatment device by the
unblinded clinician. Assignment to active or control
group was determined by telephone call by the unblinded
clinician to the trial sponsor, and was balanced in blocks
of 4 for each site and gender. The proper use of the device
was demonstrated to the participant by the unblinded cli-
nician. After experiencing the assigned device in opera-
tion, the participant completed a brief questionnaire
about expectations [21]. Participants were given a tape 20
inches in length to indicate the correct distance from the
device.
The active treatment consisted of a Litebook treatment
device with 60 LEDs (The Litebook Company Ltd.,
Alberta, Canada). The 60 LEDs employed in this Litebook
model contain emitters which have a spectral emission
peak at approximately 464 nm and fluorescent phosphors
which provide a broader, secondary spectral peak near
564 nm: of the energy emitted over the range 400 to 700
nm, about 48% is emitted over the range 420 to 508, and
37% is emitted over the range 512 to 616 nm. Collectively
the emitted light appears white. This device produces
approximately 1,350 lux light at 20 inches. Participants
assigned to this device were carefully instructed on align-
ing the device to illuminate maximally the eyes. An evalu-
ation by an independent consultant physicist confirmed
that the Litebook device meets the relevant sets of stand-
ards for light exposure safety [22-24].
Control treatment consisted of a negative ion generator,
modified to emit no negative ions (SphereOne, Inc., Silver
Plume, CO) and to generate a faint high-pitched whine,
used at the same distance. Participants using the ion gen-
erator were instructed to wear a wrist strap connected to
the device to maximize the transfer of negative ions, as
this intervention has been found to increase expectations
regarding efficacy for the device [3].
Participants were instructed to use the device for 30 min-
utes each morning, as soon as possible upon arising, and
to complete treatment before 8 A.M. Participants were
asked to maintain as stable a schedule of sleep and treat-
ment as possible during the trial, and were asked to com-
plete a log of the times of the beginning and end of sleep
and of treatment. Participants were asked not to disclose
to the blinded clinician which treatment device they were
assigned. The blinded study clinician was permitted to
reduce the duration of treatment to 15 minutes per day
until the next study visit in the event of jitteriness or over
stimulation, but this reduction was not required for any
participant during the trial.
Statistical analysis
SIGH-SAD scores were analyzed in both a last observation
carried forward (LOCF) analysis, including all 26 partici-
pants who were randomized, and an observed cases (OC)
analysis, including all 23 participants who completed the
trial. Remission was defined as a SIGH-SAD score less
than 9. The a priori endpoint hypothesis was whether the
proportion of participants in remission differed between
the active and control treatment groups in the LOCF anal-
ysis using the Fisher's exact test. In a secondary analysis,
end trial SIGH-SAD scores, as %SIGH-SAD scores consist-
ing of final score as percentage of individual score at ran-
domization, were compared between active and control
groups by t test. Post hoc comparisons of the proportion of
participants in remission and mean %SIGH-SAD scoreBMC Psychiatry 2007, 7:38 http://www.biomedcentral.com/1471-244X/7/38
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were made at Weeks 1, 2 and 3. Secondary analysis also
included a repeated measures ANOVA mixed model with
SIGH-SAD as dependent variable and time, treatment,
and interaction of time and treatment as fixed effects,
including all randomized participants. A variety of models
were considered, including participant intercept and slope
as random effects, autoregressive time-dependent, com-
pound symmetry or unstructured correlation structures,
and possible transformation of time by the log of one plus
the week of treatment. The best model was selected by
Schwartz Bayesian criterion, but all models indicated a
significant interaction of time by treatment. The final
model included linear time trend, no random effects,
transformed time, and autoregressive correlation structure
(SAS PROC MIX procedure, Kenward-Rogers method for
degrees of freedom). Statistical assumptions were verified
by examination of residuals.
Comparisons between the groups at baseline were made
with t-tests in the case of continuous variables and Fisher
exact tests in the case of dichotomous variables. Changes
in time of sleep or treatment were analyzed with paired t-
tests for participants who completed the trial, excluding
one participant with incomplete sleep log data. End trial
%SIGH-SAD scores were used to assess any relationship
between therapeutic response and times of sleep or treat-
ment or other covariate. Statistical analysis was performed
with STATVIEW version 5.0.1 and SAS version 9.1.3 (both
from SAS Institute, Cary, NC). All results are reported as
means ± standard deviations.
Results
Twenty six participants were randomized into the study,
15 in the active treatment group and 11 in the control
treatment group. In the active treatment group, 1 partici-
pant withdrew after the visit Week 1 for unclear reasons,
possibly related to adverse effects of jitteriness and head-
ache or to travel plans. In the control treatment group, 1
participant was withdrawn after Week 1 due to lack of
improvement, and 1 participant was withdrawn after
Week 1 due to missed treatments related to a motor vehi-
cle accident. Thus, 23 participants completed the Week 4
visit, 14 in the active treatment group and 9 in the control
treatment group. There were no instances of accidental
unblinding of the depression rating clinicians during the
trial.
Mean SIGH-SAD scores for the active and control treat-
ment groups did not differ significantly at randomization
(28.0 ± 5.35 versus 25.1 ± 3.22, respectively; as shown in
Table 1). There were no significant differences between
the active and control groups in age (44.7 ± 12.3 years ver-
sus 47.6 ± 10.8 years), fraction of female participants
(64.3% versus 88.9%), fraction of Caucasian participants
(85.7% versus 100%; in the active treatment group, 1 par-
ticipant was Black and 1 participant Hispanic), number of
previous episodes of SAD (11.1 ± 9.9 versus 10.6 ± 9.0),
age of first SAD episode (30.3 ± 11.6 versus 35.4 ± 13.4),
weight (78.4 ± 18.0 kg versus 71.1 ± 14.1 kg), BMI (28.9
± 6.5 versus 26.1 ± 5.1), expectation scores (3.88 ± 0.70
versus 3.37 ± 0.86), or MEQ scores (51.5 ± 10.2 versus
55.2 ± 6.3).
SIGH-SAD scores improved in both groups over the 4
weeks of treatment, with active treatment participants
showing greater improvement (Table 1, Figure 1). The
proportion of participants achieving remission was signif-
icantly greater in the intent-to-treat LOCF analysis: 53.3%
versus 9.1%, p = 0.036 (the a priori endpoint hypothesis
of the trial). The proportion of participants achieving
remission was also significantly greater with active than
control treatment in the OC analysis of all randomized
participants: 57.1% versus 11.1%, p = 0.040 (Fisher's
exact test; remission defined as SIGH-SAD score <9).
There were no significant differences in proportion of par-
ticipants in remission in pairwise post hoc comparisons
prior to Week 4.
Mean %SIGH-SAD scores (final SIGH-SAD score as per-
cent of the individual participant score at randomization)
Table 1: SIGH-SAD Outcome Measures at Randomization and after 1, 2, 3 and 4 weeks of treatment.
Mean SIGH SAD score* Mean SIGH SAD score As % of randomization 
score
% Participants in remission (SIGH SAD <9)
Active Control Active Control p value Active Control p value
Randomizatio
n
2 8 . 0  ±  5 . 3 2 5 . 1  ±  3 . 2 ------
Week 1 18.6 ± 7.9 19.0 ± 7.2 67.1 ± 26.7 74.0 ± 22.5 0.527 7.1 11.1 0.999
Week 2 14.9 ± 10.0 17.9 ± 4.9 54.5 ± 36.4 71.7 ± 19.5 0.208 28.6 0.0 0.127
Week 3 11.1 ± 10.1 14.9 ± 4.2 39.0 ± 30.7 54.4 ± 17.9 0.080 42.9 11.1 0.176
Week 4 8.7 ± 8.4 13.4 ± 5.4 29.9 ± 25.4 54.4 ± 21.8 0.027** 57.1 11.1 0.040***
Notes: Observed cases analysis: for active treatment n = 14 and for placebo treatment n = 9. * interaction of time and treatment significant in 
repeated measures ANOVA as noted in text. ** comparison significant at p ≤ 0.05 by t test. *** comparison significant at p ≤ 0.05 by Fisher's exact 
test.BMC Psychiatry 2007, 7:38 http://www.biomedcentral.com/1471-244X/7/38
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were significantly different between the active and control
groups at trial end, in both the intent-to-treat LOCF anal-
ysis, 34.5% ± 30.47% versus 60.4% ± 23.61%, p = 0.028,
and the OC analysis, 29.9% ± 25.4% versus 54.4% ±
21.8%, p = 0.027. Mean %SIGH-SAD scores did not differ
significantly in pairwise post hoc comparisons prior to
Week 4. Analysis of SIGH-SAD scores with a repeated
measures ANOVA indicated a significant effect of time (F
(1,115) = 71.2, p < 0.0001) and a significant interaction
of treatment and time (F(1,115) = 5.30, p = 0.023). These
results indicate that the active light treatment condition
was significantly superior to the placebo control condi-
tion.
There was no significant correlation between expectation
scores and therapeutic response measured as final
%SIGH-SAD scores: for all participants, r2 = 0.00 (p =
0.86), for participants on active treatment, r2 = 0.07 (p =
0.35), and for participants on control treatment, r2 = 0.03
(p = 0.63). There was no significant correlation between
pre-treatment MEQ scores and therapeutic response meas-
ured as %SIGH-SAD scores for all participants, r2 = 0.03 (p
= 0.45), for participants on active treatment, r2 = 0.00 (p =
0.79), or for participants on control treatment, r2 = 0.00 (p
= 0.84).
Times of self-reported sleep start, sleep midpoint, sleep
end, and treatment start are shown in Table 2 for all par-
ticipants who completed the trial, for the week before
treatment, the first week of treatment and the last week of
treatment in Table 2. There was no significant difference
between active and control groups in any of these varia-
bles in any week. There were no significant changes in
time of sleep start between the baseline week and first
week of treatment, or between the first and last week of
treatment in either group. The time of sleep end was ear-
lier in the first week of treatment than in the baseline week
in both active and control groups (within-group differ-
ence significant at p < 0.0001 and p = 0.047, respectively,
paired t test), presumably reflecting the need to complete
treatment by 8 A.M. as required by the protocol. Between
the first and last week of treatment the time of sleep end
shifted somewhat later in the active group (p = 0.011,
paired t test). Times of sleep midpoint and of treatment
start showed a similar pattern to time of sleep end, as
might be expected.
There was no significant statistical correlation or apparent
relationship between end trial %SIGH-SAD and time of
treatment (r = 0.01, p = 0.74), in participants on active
Table 2: Mean times of sleep and treatment during baseline week and during first and last weeks of treatment.
Sleep onset time Sleep midpoint time Sleep end time
Active Placebo Active Placebo Active Placebo
Baseline week 23:04 ± 1:01 23:08 ± 0:50 3:06 ± 0:441 3:17 ± 0:59 7:07 ± 0:512 7:26 ± 1:22
First week treatment 23:11 ± 0:45 22:58 ± 0:30 2:48 ± 0:321 2:57 ± 0:46 6:25 ± 0:402,3 6:56 ± 1:14
Last week treatment 23:05 ± 0:49 22:58 ± 0:60 2:52 ± 0:38 2:55 ± 0:55 6:39 ± 0:443 6:52 ± 0:60
Time of treatment Time to treatment after midpoint of sleep
Active Placebo Active Placebo
First week treatment 6:42 ± 0:444 7:03 ± 0:45 3:54 ± 0:295 4:03 ± 0:34
Last week treatment 6:55 ± 0:454 7:07 ± 0:50 4:01 ± 0:285 4:02 ± 0:35
Notes: Data is included for all participants who completed the trial, n = 14 for active and n = 9 for placebo treatment. No comparison between 
active and placebo group was statistically significant for any of the variables shown. Comparisons between the first week treatment and the baseline 
week or last week of treatment that were significant at p ≤ 0.05 in paired t test are indicated by shared superscripts.
Mean %SIGH-SAD Score after 1, 2, 3 and 4 weeks of treat- ment Figure 1
Mean %SIGH-SAD Score after 1, 2, 3 and 4 weeks of 
treatment. The mean SIGH-SAD score, as percent of indi-
vidual participant value at the Randomization Visit, is shown 
for participants receiving active (n = 14) and placebo (n = 9) 
treatment in the observed cases analysis, at the Randomiza-
tion Visit ("R") and after 1, 2, 3 and 4 weeks of treatment. 
Error bars indicate standard error of the mean.
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treatment who completed the trial. Most participants (11
of 15) received treatment between 6:10 A.M. and 7:40
A.M., and all of these showed a response with final score
less than 50% of pre-treatment. There was no significant
statistical correlation or apparent relationship between
end trial %SIGH-SAD and the interval between time of
treatment and sleep midpoint (r = 0.03, p = 0.53), in com-
pleting participants on active treatment. Most participants
(11 of 15) received treatment beginning between 3:20 and
4:30 hours after sleep midpoint and all but 1 had a final
%SIGH-SAD score less than 50% of pre-treatment.
Few treatment-related adverse effects were reported dur-
ing the trial. In the active treatment group, jitteriness and
headache were reported by 1 participant at Week 1, dry
mouth and difficulty falling asleep by another participant
at Week 1. In the control treatment group, jitteriness was
reported by 1 participant at Week 1.
Discussion
The results of this pilot study suggest that 30 minutes of
daily light exposure to the Litebook LED device is effica-
cious in the treatment of SAD: the a priori hypothesis of a
difference in remission rate between active and control
treatment was supported. The rate of remission in the
active group, 57%, was comparable to the remission rate
observed by Eastman et al [4] with 1 hour daily use of a
5,000 lux light box (61%). Recent studies have indicated
that the human circadian rhythm system is most sensitive
to short wavelength light. For example, melatonin secre-
tion is most powerfully inhibited by light with wavelength
in the range 450 – 480 nm [9,11], and melatonin rhythms
are best shifted by such wavelengths [10]. One study
found light with wavelengths around 468 nm more effec-
tive in the treatment of SAD than light with wavelengths
around 654 nm [13]. The spectral energy distribution of
light emitted by the Litebook LED device peaks at about
464 nm, and 48% of its energy is in the range of 420 nm
to 508 nm. It is reasonable to hypothesize that the LED
device is therapeutically similar to the brighter light box
due to this concentration in the short wavelengths. Dem-
onstration that the therapeutic effect of the Litebook
device is similar to that of a standard light box would
require direct comparison trials.
Therapeutic response with the Litebook device appeared
to be gradual, with separation of the active and control
groups increasing between 1 and 4 weeks. Our results are
similar to those of Eastman et al [4], who observed a sig-
nificant difference in response rate at Week 3 and 4. Most
studies of light therapy for SAD have been 1 or 2 weeks in
duration, but gradual onset of response was observed in
the 4 week trial by Bauer et al [25], and in the 8 week trial
by Lam et al [5]. It is possible that an 8 week trial would
have shown a further increased therapeutic response.
There is some evidence that trial length may affect speed
of therapeutic effect in light therapy, with participants
randomized to shorter treatment having a faster response
than those randomized to longer treatment [26].
Selection of an appropriate control has been problematic
in light treatment research, since, as in the case of some
other medical devices, the modality of treatment cannot
be "blind". Most such research has used treatment with
dim red light as a placebo intervention. There are 2 prob-
lems with this approach. First, as the use of bright light is
increasingly recognized by the public as a treatment for
SAD, participants may become more likely to perceive
dim red light as the placebo condition, while participants
exposed to bright light may be more likely to conclude
they are receiving the active condition. Second, even dim
light can affect the circadian rhythm system and may have
some positive therapeutic effect [27]. The present study
used a "credible placebo" design. A no-light device with a
plausible therapeutic mechanism served to control for
non-specific behavioral effects of light therapy (e.g., sit-
ting for 30 minutes, waking before 8:00 A.M.). Expecta-
tions for the light device were not significantly higher than
for the ion generator, and there was no significant correla-
tion between expectation score and therapeutic response.
The relationships between therapeutic response and times
of sleep and of treatment are important for theoretical and
practical issues. It has been proposed that SAD is related
to a phase delay of circadian rhythms, and that light treat-
ment in SAD is effective by advancing circadian rhythms
[28]. Terman and colleagues [29] observed a shift to ear-
lier time of sleep midpoint during light treatment for SAD,
suggesting a phase advance of circadian rhythm. In the
present trial we observed only a shift towards later time of
sleep end and midpoint during the 4 weeks of treatment.
In the present trial, participants in both active and control
groups appeared to move their times of awakening earlier
between the pre-treatment week and the first week of
treatment, likely because they were required to complete
treatment by 8 A.M. Light treatment then appeared to be
associated with a small delay in time of awakening during
the treatment period. The protocol of the trial may have
obscured the ability to observe shifts in circadian phase.
The observations of Terman et al [29] would suggest that
response to treatment ought to be strongest about 1.5 – 2
hours after sleep midpoint in a participant with typical 11
P.M to 7 A.M. sleep cycle. The present results do suggest
that treatment between 6:10 and 7:40 A.M. in clock time,
or between 3:20 and 4:30 hours after sleep midpoint, was
effective in alleviating SAD. With the limited number of
participants in this trial it is not possible to draw detailed
conclusions about the dependence of therapeutic
response on time of treatment. Studies with other meth-BMC Psychiatry 2007, 7:38 http://www.biomedcentral.com/1471-244X/7/38
Page 7 of 8
(page number not for citation purposes)
odologies, such as that of Murray et al [30], have not
observed relationships like those observed by Terman et al
[29]. A more detailed version of the phase shift hypothesis
suggests that the relationship between times of sleep and
time of temperature minimum is critical in the pathogen-
esis and treatment of SAD [31]. We were unable to meas-
ure any such shift in phase angle difference as there was
no measure of physiological rhythms in our participants
(nor did we measure end trial MEQ, which might serve as
a surrogate measure). There was no discernable relation-
ship between MEQ and therapeutic response to light treat-
ment. A study of this size might not be adequate to detect
such an association.
Reports of adverse events were rare in the trial and the
light treatment was well tolerated by participants. Jitteri-
ness was observed in 1 participant each in the active and
control treatment groups. This trial is too small to permit
accurate assessment of a difference in the occurrence of
this symptom between active and control treatment. No
ocular adverse events were observed. Studies with oph-
thalmological examination before and after treatment
have disclosed no harmful effect of treatment with con-
ventional light boxes [32], but such studies have not been
conducted with the Litebook device.
In summary, this pilot randomized controlled trial sup-
ported the hypothesis that the Litebook LED device is sig-
nificantly superior to a credible placebo control condition
for the treatment of SAD. However, the results of a small-
sample clinical trial must be interpreted with caution. A
trial with a larger sample size would provide more defini-
tive information about the efficacy and safety of this LED
device. A more convenient form of light therapy might
lead to increased use of light for SAD and other biological
rhythm disturbances.
Conclusion
At the end of this 4 week randomized, double-blind, pla-
cebo-controlled trial, the proportions of participants in
remission (SIGH-SAD < 9) were significantly greater, and
SIGH-SAD scores (as percent of individual score at rand-
omization) were significantly lower with treatment with
the Litebook LED light therapy device than with placebo
treatment. A longitudinal repeated measures ANOVA
analysis of SIGH-SAD scores also indicated a significant
interaction of time and treatment. These results are con-
sistent with the hypothesis that the Litebook device is an
effective therapy for SAD. There was no significant corre-
lation between therapeutic response and expectation
scores, MEQ scores, or time of treatment expressed as
clock time, or as time since the midpoint of sleep. Treat-
ment was well-tolerated, with only transient minor
adverse effects.
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